A Phase 1 trial found that combining the ATR inhibitor ceralasertib with the PARP inhibitor olaparib was generally well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results